Multiple Sclerosis Research Center

The Multiple Sclerosis Research Center focuses on the study of Experimental Autoimmune Encephalomyelitis (EAE) as an animal model of Multiple Sclerosis. Specific research areas include the role of proinflammatory cytokines, such as interleukin- 12 (IL- 12), IL- 23, and their receptors in the pathogenesis of EAE, the mechanisms of intravenous immune tolerance induced by myelin proteins, and the role of the Insulin-like Growth Factor (IGF) in central nervous system remyelination.

Another area of research in collaboration with the Department of Radiology is the use of novel imaging modalities for EAE, such as the combined use of high- field magnetic resonance imaging (MRI) and positron emission tomography (PET) to track autoimmune T cells in vivo. In addition to basic studies of neuro-immunology and neurobiology in EAE, the Multiple Sclerosis Research Center will also conduct immunologic studies in MS patients undergoing conventional and experimental therapies. This is done in collaboration with the Multiple Sclerosis Comprehensive Clinical Center.

A Randomized, Double-Blind, Placebo-Controlled, Dose-Titration S Assess the Safety, Tolerability, and Efficacy of C105 in Persons with Sclerosis with Cognitive Impairment

Examining the Relationship Between MS Progression and Driving.

An International, Multi-Center, Double-Blind, Parallel-Group, Placebo-Controlled Study to Evaluate the Efficacy and Safety of Teriflunomide 7 mg Once Daily and 14mg Once Daily Versus Placebo in Patients with Relapsing Multiple Sclerosis using Interferon-Beta 1a (Rebif) as an Open-Label Rater-Blind Calibrator.

An Observational 20 Year, Cross-Sectional, Long Term Follow-Up of the Patient Cohort Enrolled in the Pivotal Study of Betaseron (Interferon Beta-1b) in Relapsing-Remitting Multiple Sclerosis.

A Phase III, Multicenter, Double-Blind, Placebo-Controlled Randomized Discontinuation Study Followed by an Open Label Extension Period to Evaluate the Efficacy and Safety of Amifampridine Phosphate (3,4-Diaminopyridine Phosphate) in Patients with Lambert-Eaton Myasthenic Syndrome

JCV Antibody Program in Patients with Relapsing Multiple Sclerosis Receiving or Considering Treatment with Tysabri: STRATIFY-2

Explore More at Jefferson

The Web site for Thomas Jefferson University, its contents and programs, is provided for informational and educational purposes only and is not intended as medical advice nor, is it intended to create any physician-patient relationship. Please remember that this information should not substitute for a visit or a consultation with a healthcare provider. The views or opinions expressed in the resources provided do not necessarily reflect those of Thomas Jefferson University Hospitals, Thomas Jefferson University or their staffs. By using this Web site, you accept these terms of use. Please read our online privacy statement. Please read our our privacy practices.